-
Company Profile
Environmental Tectonics Corp – Company Profile
Environmental Tectonics Corp (ETC) designs, develops and markets simulation systems for aerospace and automotive industries. The company’s product portfolio comprises aircrew training systems, authentic tactical fighting systems, altitude (hypobaric) chambers, advanced disaster management simulators, environmental testing and simulation systems, air and space adventures, composites, and sterilization systems. It serves clients in the areas of aero medical, automotive testing, advanced pilot training, emergency response, HVAC, life sciences, medical devices, pharmaceutical devices, and space. The company operates in the UK, the Netherlands,...
Add to Basket -
Company Profile
Atlantica Sustainable Infrastructure plc – Company Profile
Atlantica Sustainable Infrastructure plc (Atlantica), formerly Atlantica Yield plc, is a sustainable infrastructure company. It owns, manages and acquires a portfolio of contracted assets in the power and environment sectors. The company owns various assets comprising renewable energy generation, conventional power generation, efficient natural gas, electric transmission lines and water assets. Atlantica’s asset portfolio includes Solana, Mojave, Solaben, Helios, Solnova, Kaxu, Palmatir, Cadonal, ATN, ATS, Quadra, Palmucho, Skikda and Honaine. It has operations in North America, South America, Europe and...
Add to Basket -
Product Insights
Mangalore V liquids storage terminal, India
Mangalore V liquids storage terminal is located in Karnataka, India. It started operations in 2017. Empower your strategies with our Mangalore V liquids storage terminal, India report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ION-582
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ION-582 Drug Details ION-582 is under development for the treatment of Angelman syndrome. It...
-
Product Insights
Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. This damage allows bacteria and mucus to build up in the lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss, and fever. The Bronchiectasis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Bronchiectasis, Â complete with analysis by stage of development, drug target,...
-
Product Insights
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis – Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe...
-
Product Insights
Alpha-1 Antitrypsin Deficiency (A1AD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha-1 Antitrypsin Deficiency (A1AD) pipeline market research report provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alpha-1 Antitrypsin...
-
Product Insights
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores, and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids. The Granulomatosis with Polyangiitis drugs in development market research report provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis, complete with analysis by stage of development, drug target, mechanism of...
-
Product Insights
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. The Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) Development market research report provides an in-depth analysis of...
-
Product Insights
Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The acute respiratory distress syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute...